NuCana company info

What does NuCana do?
NuCana (NASDAQ:NCNA) is a biopharmaceutical company focused on significantly improving treatment outcomes for cancer patients by applying its proprietary ProTide technology to transform some of the most widely used chemotherapy agents into more effective and safer medicines. While primarily listed on the NASDAQ stock exchange, this innovative firm is dedicated to advancing a broad and deep pipeline, centered around transformative oncology drug candidates. Their projects aim to tackle various cancer types, with an ongoing commitment to both research and development in striving to meet unmet medical needs within the oncology space. NuCana's objectives are clearly defined around pushing the boundaries of what current treatments can achieve, aiming to offer new hope and possibilities for patients facing cancer.
NuCana  company media
Company Snapshot

Is NuCana a public or private company?

key
Ownership
Public

How many people does NuCana employ?

people
Employees
27

What sector is NuCana in?

pie chart
Sector
Health Care

Where is the head office for NuCana ?

location pin
Head Office
Edinburgh, United Kingdom

What year was NuCana founded?

founded flag
Year Founded
1997
What does NuCana specialise in?
/Cancer Therapies /Biopharmaceutical Company /ProTide Technology /Chemotherapy Treatments /Clinical Trials /Drug Development

What are the products and/or services of NuCana ?

Overview of NuCana offerings
Acelarin, a nucleotide analogue designed for the treatment of various cancers, including ovarian, pancreatic, and biliary.
NUC-3373, a next-generation fluoropyrimidine aimed at enhancing treatment for colorectal cancer and other solid tumors.
NUC-7738, a novel compound transforming a naturally occurring nucleoside into a potential treatment for hematological and solid cancers.
Development of proprietary ProTide technology, enhancing anti-cancer agents' efficacy by bypassing resistance mechanisms.
Collaboration with major pharmaceutical and research institutions for the advancement of oncology treatments.
Ongoing clinical trials assessing the effectiveness and safety of their leading compounds in various stages of development.

Who is in the executive team of NuCana ?

NuCana leadership team
  • Mr. Hugh Stephen Griffith
    Mr. Hugh Stephen Griffith
    Founder, CEO & Executive Director
  • Mr. Donald  Munoz
    Mr. Donald Munoz
    Chief Financial Officer
  • Mr. David  Harrison
    Mr. David Harrison
    Head of Translational Medicine
  • Dr. Jeffrey D. Bloss F.A.C.O.G., M.D.
    Dr. Jeffrey D. Bloss F.A.C.O.G., M.D.
    Chief Medical Officer
  • Ms. Theresa  Bruce
    Ms. Theresa Bruce
    Senior Vice President of Clinical Operations
  • Ms. Elisabeth  Oelmann
    Ms. Elisabeth Oelmann
    Senior Vice President of Medical & Clinical Development
  • Martin  Quinn
    Martin Quinn
    Company Secretary